Global Market Bulletin
  • Home
  • Stock Market News
  • Investing
  • Economy
  • CEO Interviews
  • Contact Us
No Result
View All Result
SUBSCRIBE
Global Market Bulletin
  • Home
  • Stock Market News
  • Investing
  • Economy
  • CEO Interviews
  • Contact Us
No Result
View All Result
Global Market Bulletin
No Result
View All Result
Home Stock Market News

Top 10 Cheap Large-Cap Stocks Under $100 to Buy Now

by Global Market Bulletin
May 17, 2026
in Stock Market News
0
Top 10 Cheap Large-Cap Stocks Under $100 to Buy Now

Top 10 Cheap Large-Cap Stocks Under $100 to Buy Now

55
SHARES
119
VIEWS
Share on FacebookShare on Twitter

9. Ventas Inc. (NYSE:VTR)

Ventas Inc. (NYSE: VTR) ranks No. 9 among the best large-cap stocks to buy under $100, and its story is very different from the usual technology-heavy names that dominate market headlines. Trading at $87.46, with a 2.78% decline based on the provided data, Ventas is a healthcare-focused real estate investment trust, or REIT, that gives investors exposure to one of the most important demographic trends in North America: the aging population. For investors searching for REIT stocks under $100, healthcare REIT stocks, large-cap dividend stocks, senior housing stocks, and real estate stocks to buy, Ventas stands out because its latest results suggest that demand in senior housing remains healthy and that the company’s portfolio is benefiting from improving occupancy, stronger operating revenue, and expanding margins.

You might also like

5 Most Profitable Energy Stocks to Buy in 2026

10 Most Profitable Energy Stocks to Buy in 2026

Here’s What Makes Iovance Biotherapeutics (IOVA) a Smart Long-Term Buy

On April 27, Ventas reported strong financial results for the first quarter of 2026, with the company’s senior housing operating portfolio, also known as SHOP, serving as the major growth engine. The company posted net income attributable to common stockholders of $0.11 per share and Normalized Funds From Operations, or FFO, of $0.94 per share. That represented a 9% increase compared with the same period in the prior year. In the REIT world, FFO is often more important than traditional earnings per share because real estate companies carry large depreciation charges that can distort reported net income. For income-focused investors and long-term real estate investors, Normalized FFO gives a clearer view of recurring operating performance.

Ventas also reported a 14% year-over-year increase in total company net operating income, while total same-store cash net operating income rose by 9%. That matters because same-store NOI helps investors evaluate the performance of properties that were already in the portfolio, rather than growth that only came from acquisitions. In simple terms, Ventas is not just getting bigger. Its existing properties are performing better. That is a key distinction for any investor looking at best large-cap REIT stocks to buy, especially in a market where interest rates, borrowing costs, and property valuations remain important concerns.

The most important driver was the SHOP segment, which delivered a same-store cash NOI increase of more than 15% year-over-year. This growth was supported by a 9% increase in same-store cash operating revenues, 170 basis points of NOI margin expansion, and a 310 basis point improvement in average occupancy. Those details matter because senior housing is a very operationally sensitive business. Small improvements in occupancy can have a meaningful effect on profitability because many property-level expenses are relatively fixed. When more units are occupied, revenue improves, margins can expand, and cash flow can become stronger.

There is also a major demographic trivia behind this investment case. Senior housing is often tied to the aging of the baby boomer generation, one of the largest population cohorts in American history. As more people move into older age brackets, demand for senior housing, assisted living, and healthcare-related real estate may continue to rise. Of course, not every senior housing operator or healthcare REIT will benefit equally. Costs, staffing, location, property quality, operator relationships, and balance sheet discipline still matter. But Ventas appears to be capturing momentum at a time when the industry’s long-term demand profile remains structurally attractive.

Because of its strong property performance and investment pipeline, Ventas raised its 2026 investment volume expectations to $3.0 billion. The company had already closed $1.7 billion in senior housing investments year-to-date through April. That shows management is not sitting still. It is actively deploying capital into areas where it sees opportunity. For a REIT, acquisitions can create value when they are done at attractive yields, financed responsibly, and integrated into a portfolio with improving operating trends. Ventas appears to be leaning into the senior housing recovery theme while maintaining a focus on financial flexibility.

The company also increased its full-year 2026 guidance, projecting a revised Normalized FFO per share midpoint of $3.86 and an attributable net income per share midpoint of $0.60. Just as important, Ventas improved its net debt-to-further adjusted EBITDA ratio to 5.0x, marking its tenth consecutive quarter of sequential improvement. In a higher-rate environment, debt levels matter a lot for REITs. Investors are not only looking for growth; they also want to know whether the company can fund that growth without overburdening the balance sheet. Ventas’ improved leverage profile gives it a stronger case as one of the best large-cap stocks under $100 for long-term investors.

Ventas owns around 1,400 properties across North America and the United Kingdom, including senior housing communities, outpatient medical buildings, research centers, hospitals, and other healthcare facilities. That broad portfolio gives the company exposure to multiple healthcare real estate categories, but the current story is clearly being driven by the strength of senior housing. For investors who want a stock under $100 with a real estate angle, healthcare exposure, and a demographic tailwind, Ventas remains a name worth watching closely.

Click next to see the following stock...

Page 2 of 5
Prev123...5Next
Tags: Arch Capital Group Ltd. (NASDAQ:ACGL)Crown Castle Inc. (NYSE:CCI)Daily NewsletterGuardant Health Inc. (NASDAQ:GH)HeadlineMicrochip Technology Inc. (NASDAQ:MCHP)NASDAQ:ACGLNASDAQ:GHNASDAQ:MCHPNYSE:CCINYSE:VTRTop 10 Cheap Large-Cap Stocks Under $100 to Buy NowVentas Inc. (NYSE:VTR)Yahoo Finance
Share22Tweet14

Global Market Bulletin

Global Market Bulletin is a leading provider of stock market updates, economic news, and personalized investing guides. Our team brings you the latest global financial information to help you make smart investment decisions. About the Editorial Team Our editorial team consists of financial experts and seasoned market analysts who bring decades of experience to our coverage. With a commitment to unbiased reporting, our team ensures that every article is backed by thorough research and delivers accurate financial insights.

Recommended For You

5 Most Profitable Energy Stocks to Buy in 2026

by Global Market Bulletin
June 12, 2026
0
5 Most Profitable Energy Stocks to Buy in 2026

In this article, we break down the 5 Most Profitable Energy Stocks to Buy in 2026. For investors looking for the complete list, you can explore our full...

Read moreDetails

10 Most Profitable Energy Stocks to Buy in 2026

by Global Market Bulletin
June 12, 2026
0
10 Most Profitable Energy Stocks to Buy in 2026

In this article, we will take a look at the 10 Most Profitable Energy Stocks to Buy in 2026. Every market cycle has its surprise winner, and in...

Read moreDetails

Here’s What Makes Iovance Biotherapeutics (IOVA) a Smart Long-Term Buy

by Global Market Bulletin
June 6, 2026
0
Here’s What Makes Iovance Biotherapeutics (IOVA) a Smart Long-Term Buy

We recently published our article Top 5 Heavily Shorted Small-Cap and Mid-Cap Stocks to Buy Today. To read the full story, you can go directly to  Top 10...

Read moreDetails

Is Capricor Therapeutics (CAPR) a Smart Biotech Stock to Buy Before Its Next Catalyst?

by Global Market Bulletin
June 6, 2026
0
Is Capricor Therapeutics (CAPR) a Smart Biotech Stock to Buy Before Its Next Catalyst?

We recently published our article Top 5 Heavily Shorted Small-Cap and Mid-Cap Stocks to Buy Today. To read the full story, you can go directly to  Top 10...

Read moreDetails

Here’s What Makes ImmunityBio (IBRX) a High-Upside Biotech Stock Investors Should Watch Closely

by Global Market Bulletin
June 6, 2026
0
Here’s What Makes ImmunityBio (IBRX) a High-Upside Biotech Stock Investors Should Watch Closely

We recently published our article Top 5 Heavily Shorted Small-Cap and Mid-Cap Stocks to Buy Today. To read the full story, you can go directly to  Top 10...

Read moreDetails

Browse by Category

  • CEO Interviews
  • Economy
  • Investing
  • Stock Market News
  • Uncategorized

QUICK LINKS

  • Stock Market News
  • Investing
  • Economy
  • Contact Us
  • About Global Market Bulletin
  • Editorial Policy – Global Market Bulletin
  • Our Editorial Team

RECENT POSTS

  • 5 Most Profitable Energy Stocks to Buy in 2026
  • 10 Most Profitable Energy Stocks to Buy in 2026
  • Here’s What Makes Iovance Biotherapeutics (IOVA) a Smart Long-Term Buy

GET EMAIL MARKET UPDATES

Subscribe to our mailing list to receives daily updates direct to your inbox!
  • Privacy Policy
  • Terms and Conditions

© 2022 Global Market Bulletin. All Rights Reserved.

No Result
View All Result
  • Home
  • Stock Market News
  • Investing
  • Economy

© 2022 Global Market Bulletin. All Rights Reserved.

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?